Bio-Techne Corp TECH has recently faced some challenges with its shares experiencing a slight dip following multiple headwinds in Q1. However, the company's shares have also climbed by 33%, showcasing strong resilience. Furthermore, Bio-Techne has been acing acquisitions by giants like PNC Financial Services Group and Truist Financial Corp. Citigroup has downgraded the company to 'neutral', citing valuation concerns. Regardless, the company's performance in Q3 2024 exceeded expectations. It has been involved in top-line biomarker data discussions with partner, Regulus. The company has also signed a new distribution agreement with Thermo Fisher Scientific. Bio-Techne's RNAscope technology has surpassed 10,000 peer-reviewed citations. The corporation has also amassed impressive partnerships with the likes of Nikon Instruments Inc. and announced Bio-Techne's appointment of Kim Kelderman as CEO and Matthew F. McManus as President, Diagnostics. Despite a few negative perspectives, Bio-Techne remains a strong contender in the biotech sector, with share estimates rated 25% to 32% above their intrinsic value.
Bio-Techne Corp TECH News Analytics from Fri, 18 Nov 2022 08:00:00 GMT to Thu, 23 May 2024 19:57:27 GMT - Rating 3 - Innovation 6 - Information 7 - Rumor -4
